You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Skp2 is a Promising Therapeutic Target in Breast Cancer
|
|---|---|
| Published in |
Frontiers in oncology, January 2012
|
| DOI | 10.3389/fonc.2011.00057 |
| Pubmed ID | |
| Authors |
Zhiwei Wang, Hidefumi Fukushima, Hiroyuki Inuzuka, Lixin Wan, Pengda Liu, Daming Gao, Fazlul H. Sarkar, Wenyi Wei |
| Abstract |
Breast cancer is the most common type of cancer among American women, and remains the second leading cause of cancer-related death for female in the United States. It has been known that several signaling pathways and various factors play critical roles in the development and progression of breast cancer, such as estrogen receptor, Notch, PTEN, human epidermal growth factor receptor 2, PI3K/Akt, BRCA1, and BRCA2. Emerging evidence has shown that the F-box protein S-phase kinase associated protein 2 (Skp2) also plays an important role in the pathogenesis of breast cancer. Therefore, in this brief review, we summarize the novel functions of Skp2 in the pathogenesis of breast cancer. Moreover, we provide further evidence regarding the state of our knowledge toward the development of novel Skp2 inhibitors especially natural "chemopreventive agents" as targeted approach for the prevention and/or treatment of breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Denmark | 1 | 1% |
| Unknown | 66 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 22% |
| Researcher | 15 | 22% |
| Student > Master | 7 | 10% |
| Student > Bachelor | 5 | 7% |
| Student > Postgraduate | 3 | 4% |
| Other | 9 | 13% |
| Unknown | 14 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 22 | 32% |
| Biochemistry, Genetics and Molecular Biology | 14 | 21% |
| Medicine and Dentistry | 7 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Unspecified | 1 | 1% |
| Other | 5 | 7% |
| Unknown | 17 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 January 2012.
All research outputs
#22,758,309
of 25,373,627 outputs
Outputs from Frontiers in oncology
#15,917
of 22,416 outputs
Outputs of similar age
#228,487
of 250,101 outputs
Outputs of similar age from Frontiers in oncology
#100
of 161 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,416 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,101 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 161 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.